Recent Updates — MRAI

Marpai, Inc. entered into securities purchase agreements with accredited investors to sell 12,100 shares of newly designated Series A Preferred Stock at $1,000 per share, generating approximately $12,100,000 in gross proceeds. The initial closing is expected on July 31, 2026. Each preferred share converts into common stock at a price of $1.00 and carries an 8% dividend payable in common stock upon liquidity events or conversion. Mitchell Companies led the investment, with Steve Mitchell appointed as a board observer for two years under a separate agreement. The company agreed to file a registration statement within 60 days of closing. Marpai operates in the healthcare technology industry, providing Third-Party Administration and Pharmacy Benefit Management services.

Marpai, Inc. entered into debt restructuring agreements with principal lenders JGB Capital and AXA S.A. to reduce near-term debt service by $26.4 million through 2027. The AXA Amendment, dated July 16, 2026, extends maturity to December 31, 2029, establishes minimum annual payments of $0 for 2026, $1 million for 2027, $5 million for 2028, and $22.25 million for 2029, and restricts additional indebtedness. The JGB agreement extends the maturity date of debentures to April 15, 2028. Marpai is a healthcare technology company providing TPA, PBM, and health plan services to employers.